A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4831 After Multiple Ascending Dose Administration to Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2017
At a glance
- Drugs AZD 4831 (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 01 Dec 2017 Status changed from active, no longer recruiting to completed.
- 08 Nov 2017 Planned End Date changed from 17 Nov 2017 to 21 Nov 2017.